NSAIDs are readily available analgesics that are likely taken by many women in the postpartum period. Nonselective NSAIDs are listed as compatible with breastfeeding by the American Academy of Pediatrics,5 and the cyclooxygenase (COX)-2 selective NSAIDs are considered to be probably compatible with lactation.6 In contrast, it is advised that aspirin be used with caution4,6 or avoided when breastfeeding.7 Both NSAIDs and aspirin are believed to exert their effect primarily through inhibition of COX enzymes.
In this review, the evidence supporting the safety and effectiveness of NSAIDs and aspirin during pregnancy and the postpartum period, during lactation initiation, is evaluated. The review covers the drugs’ effects on fertility, on the fetus during early pregnancy and the second and third trimesters, and on the neonate or breastfed infant. Where appropriate, conclusions drawn about use of NSAIDS during pregnancy and the early postpartum period indicate the level of evidence supporting them.b
Because of its antiplatelet and anti-inflammatory actions, it has been postulated that low-dose aspirin may improve outcomes after in vitro fertilization procedures.23 A number of small randomized trials have been conducted with conflicting results.23 A meta-analysis including 9 trials involving 1449 women found no significant difference in pregnancy rate or live birth rate associated with low-dose aspirin therapy compared with placebo.24 The authors concluded that further randomized trials involving larger numbers and specific patient groups are required. The use of NSAID analgesia for oocyte retrieval during in vitro fertilization procedures is also controversial. No significant effect on pregnancy or implantation rates has been found in a number of small randomized trials.25–27 However, reduced pain immediately after the implantation procedure was noted in 1 study in which diclofenac was compared with placebo.26 Larger randomized controlled trials are required before NSAID use can be recommended in association with oocyte retrieval.
NSAIDs are readily available over-the-counter medication. The prevalence of use within the interval from preconception through the first trimester is reported to range from 2.9% to 18%.1,28,29 NSAIDs such as diclofenac and naproxen readily cross the placenta as early as the first trimester.30,31 Case-control and cohort studies have shown an increased risk of spontaneous abortion with NSAID use during early pregnancy (Table 3).32–34 However, the higher rate of spontaneous abortion does not appear to be solely a consequence of therapy for uterine cramping pain, because similar results were seen when this indication for use was excluded.33 Also, acetaminophen use was not associated with an increased risk of abortion (odds ratio [OR], 1.2; 95% confidence interval [CI], 0.8–1.8).33 Aspirin was associated with similar adverse outcomes, but the association was weaker because of the relatively small number of aspirin users.33
Cohort and case-control studies investigating the risk of congenital birth defects associated with NSAID ingestion in early pregnancy report conflicting findings (Table 4). One nested case-control study found an association with nonspecific congenital defects, but assessed only 93 cases.35 In contrast, 4 prospective cohort studies32,39–41 found no such association, although individual trials may have been underpowered. A positive association with selected congenital defects, such as cardiac anomalies36 or gastroschisis37 has been reported, but a study that specifically assessed the risk of ventricular septal defect did not find an association.38
The relationship between aspirin and birth defects is also controversial. Rats administered very high doses resulting in 5 times the therapeutic concentration range demonstrate more malformations than control rats, including central nervous system, skeletal, and vascular defects,42 and similar findings are noted in mice, rabbits, monkeys, and dogs.42 Retrospective human case-control studies report an increased incidence of congenital malformations,43,44 such as cleft lip,45 but are predisposed to significant bias.42 Large case-control studies report no association with cardiac defects (Table 5).46,47 A large prospective study that monitored 50,282 mother–child pairs, of whom 32,164 had been exposed to aspirin,48 found no evidence of a teratogenic effect. Follow-up of > 4000 children involved in the collaborative low-dose aspirin study in pregnancy (CLASP) trial of maternal low-dose aspirin to prevent preeclampsia reported no relationship between aspirin and the risk of congenital abnormalities or developmental delay.49
Preeclampsia is a relatively common disorder that affects 2% to 5% of pregnancies. The etiology of preeclampsia is still not fully understood but involves inadequate invasion of the uterine spiral arteries by the trophoblastic layer, a process that begins at 8 weeks gestation and is mostly complete by 16 to 20 weeks. An imbalance between the vasodilatory properties of prostacyclin and the vasoconstrictive action of thromboxane has been postulated as the mechanism behind this characteristic disease pattern.50 Treatment with low-dose aspirin (50–150 mg/d) to redress this imbalance has been investigated, but the outcomes of randomized controlled trials conflict. A meta-analysis of studies involving 11,348 women, published in 2010, analyzed subgroups according to gestational age at which low-dose aspirin treatment was commenced.51 Low-dose aspirin begun before 16 weeks gestation was associated with a significant risk reduction in the incidence of preeclampsia (relative risk [RR], 0.47; 95% CI, 0.34–0.65; number-needed-to-treat [NNT], 9), but if commenced after 16 weeks gestation it was not. The incidence of severe preeclampsia, intrauterine growth restriction, or preterm birth was also significantly decreased among those who began low-dose aspirin before 16 weeks. However, all the studies that included women at high risk for preeclampsia were small, and the positive findings may have been overestimated. Large randomized controlled trials adjusted by gestational age remain necessary to address this question.
Low-dose aspirin in combination with low-dose heparin is recommended for treatment of recurrent spontaneous abortion in women with antiphospholipid antibodies.c A meta-analysis, of women with antiphospholipid antibodies who had a prior miscarriage, examined all treatments used to maintain pregnancy and found that unfractionated heparin with aspirin was the only treatment combination to significantly reduce pregnancy loss.53 Three trials investigating aspirin alone found no reduction in pregnancy loss (RR, 1.05; 95% CI, 0.66–1.68), but 2 trials including 140 patients found that unfractionated heparin plus low-dose aspirin, compared with low-dose aspirin alone, reduced risk (RR, 0.46; 95% CI, 0.29–0.71).
The authors of the meta-analysis suggested performing a large randomized control trial to explore the potential differences between unfractionated heparin and low molecular weight heparin. Two small pilot trials have since been published, both reporting no significant difference in outcome between unfractionated or low molecular weight heparin combined with low-dose aspirin.54,55
Prostaglandins play an important role in the onset and maintenance of labor by enhancing the formation of myometrial gap junctions and increasing intracellular calcium. The expression of COX-1 increases dramatically in the decidua, myometrium, and fetal membranes during labor. Prostaglandin inhibitors such as indomethacin have a potent inhibitory effect on uterine contractions,56 and indomethacin has been used since the 1970s as a tocolytic to delay and treat premature delivery. Meta-analysis confirms that, compared with placebo and other tocolytics such as β-sympathomimetic drugs or magnesium sulphate, indomethacin reduces the risk of preterm birth (before 37 weeks) and causes fewer maternal side effects.57,58 However, as with other tocolytic drugs, no clear improvement in neonatal morbidity or mortality has been demonstrated.57 Furthermore, administration in the second trimester is associated with congenital cryptorchism, and short-term administration of indomethacin in the third trimester increases the incidence of premature closure of the fetal ductus arteriosus compared with placebo (OR, 15.04; 95% CI, 3.29–68.68).58 NSAID-induced constriction of the ductus arteriosus, leading to potential neonatal pulmonary hypertension, can be demonstrated after 48 hours administration from as early as 27 weeks.59 Other adverse effects of NSAIDs in later pregnancy include oligohydramnios caused by reduced fetal urine output, necrotizing enterocolitis, and intracranial hemorrhage.60 Although short-term administration of an NSAID is infrequently associated with fetal ductal constriction, many practitioners consider these drugs unsuitable for use after 28 to 32 weeks gestation.4
COX-2 inhibitors such as rofecoxib, sulindac, ketorolac, and nimesulide are also effective tocolytic drugs,57,58,60 and it was hoped that they might have fewer adverse effects than indomethacin.61 However, the same problems, including oligohydramnios and ductal constriction, remain after exposure to the COX-2 specific NSAIDs. A randomized controlled study comparing nimesulide with sulindac or indomethacin found a similar incidence of ductal constriction in all groups.61 The Royal College of Obstetricians and Gynaecologists note that COX-2 inhibitors are better tolerated than other tocolytics for preterm birth. However, due to poor effectiveness before 32 weeks gestation and increased neonatal morbidity beyond 28 weeks compared with alternative tocolytic drugs such as calcium channel blockers or oxytocin receptor antagonists, they are not recommended as first-line treatment.d However, the American College of Obstetricians and Gynecologists Practice Bulletin on management of preterm labor supports NSAIDs for short-term (up to 48 hours) prolongation of pregnancy, to allow administration of antenatal steroids.62
Although generally considered to be safe in the second trimester of pregnancy, there is low-level evidence from a recent investigation of a possible harmful effect of NSAIDs during this period. A prospective birth cohort study performed in Denmark asked 491 women to complete a questionnaire about their exposure to mild analgesics during pregnancy and demonstrated a dose-dependent association between the use of acetaminophen, aspirin, or ibuprofen and congenital cryptorchism.63 The association was more marked after second trimester use (OR, 2.20; 95% CI, 1.09–4.45) or if >1 drug was used (OR, 7.72; 95% CI, 2.09–28.6). Another questionnaire among 1463 women in Finland reported no harmful association, but the results were probably affected by both underreporting and the lower incidence of congenital cryptorchism in that country. The postulated causal mechanism is the antiandrogenic effects of prostaglandin inhibition.
Congenital cryptorchism is the best-described risk factor for poor semen quality and testicular germ cell cancer;64 so in theory, intrauterine exposure to mild analgesics might also be a risk factor for the development of male reproductive disorders.
Fetal renal dysfunction induced by NSAIDs is thought to result largely from a reversible reduction in renal blood flow and hence glomerular filtration rate, but may also be due to structural changes in the kidney resulting from antenatal exposure to NSAIDs.d,65,66 Histological examination reveals typical nephrotoxicity, with abnormal glomeruli and tubules; various degrees of ischemic injury and fibrosis in the medullary area; cortical necrosis; focal tubular and glomerular microcysts in developing nephrons; and loss of differentiation between proximal and distal tubules.67 This pathology may reflect a defect in nephrogenesis as a result of the inhibition of prostaglandin release. The COX-2 enzyme is expressed prominently by the developing fetal kidney, first appearing in midgestation and increasing in prominence toward term.68 Nephrogenesis begins from the fifth gestational week and is usually complete by 36 weeks.68 The importance of COX-2 during this phase of development is demonstrated by the fact that COX-2 null mice are born with small kidneys containing fewer nephrons, dilated atrophic tubules, and interstitial fibrosis.69,70
The renal effects of in utero exposure to NSAIDs (both selective and nonselective) vary in severity from transient fetal oligohydramnios to severe and lethal neonatal renal failure.68,71–74 Preterm infants exposed to indomethacin in utero exhibit abnormal renal function when glomerular filtration rate is assessed by inulin clearance, the “gold standard” for its measurement.66 The incidence of renal dysfunction associated with NSAID exposure in utero varies from 1.5% to 20%,75,76 increasing as exposure occurs closer to delivery. A case-control study in premature infants admitted to neonatal intensive care units investigated risk factors for neonatal renal dysfunction and identified maternal consumption of NSAIDs during pregnancy as the main independent risk factor (OR, 7.38; 95% CI, 3.26–16.7).76
High-dose aspirin (325–650 mg) taken during the week before delivery increases not only the incidence of minor neonatal bleeding episodes5 but also that of serious neonatal bleeding after premature delivery.81 An observational study of 108 infants of birth weight ≤1500 g, delivered up to and including 34 weeks gestation, found a higher incidence of intracranial hemorrhage among aspirin-exposed newborns compared with nonaspirin-exposed infants (71% vs 45%).81 Hence, high-dose aspirin should be avoided during pregnancy, particularly if there is an increased risk of premature delivery. In contrast, maternal administration of low-dose aspirin inhibits maternal platelet COX enzymes but not those of the newborn,82 so use of low-dose aspirin during pregnancy is not associated with fetal or neonatal toxicity.5
Case reports suggest deterioration of preeclampsia-related hypertension after exposure to indomethacin.83,84 The mechanism is postulated to be inhibition of prostaglandin synthesis in the renal vasculature85 and interference with the action of antihypertensive medications.85 On this basis, it has been recommended that all NSAIDs should be avoided in women with preeclampsia, as well as patients with aspirin-sensitive asthma or preexisting renal impairment.
Only 1 study has evaluated the analgesic properties of NSAIDs to treat uterine contraction pain during labor. A single dose of IM ketorolac 50 mg had poor effectiveness, similar to that of meperidine 50 to 100 mg, although the latter caused more maternal sedation and fetal depression.86 Furthermore, there are theoretical objections to NSAID administration during labor, because uterine endothelial prostaglandin F2α production and prostaglandin receptor activation are important initiators of intracellular calcium increase, actin–myosin interaction, and myometrial contraction.87 This tocolytic action raises concern about uterine atony and subsequent postpartum hemorrhage. Consequently, there appears to be no role for NSAIDs in this setting.
The NSAIDs are acidic drugs (e.g., ketorolac pKa 3.5 and indomethacin 4.5) with low lipid solubility and high protein binding (>90%), features that mitigate against substantial transfer into breastmilk, which is slightly acidic (mean pH 7.1–7.2) compared with plasma. The latter characteristic also favors drug transfer of the nonionized form back from the milk to more alkaline maternal plasma (reverse “ion-trapping”) and thus milk to plasma ratios of NSAIDs are generally <1. Such ratios, however, are not informative about the exposure of the infant to drug transferred in breastmilk. If the estimated absolute infant dose of a drug is established (by measurement of breastmilk concentration and estimation of volume of milk ingested), the relative infant dose expressed as a percentage of the maternal dose can be calculated. For some drugs, it may be possible to compare this level of dose exposure in the breastfed infant with the exposure of an infant as a result of therapeutic pediatric dosing. High protein binding and limited gastrointestinal absorption reduce systemic infant exposure to drug from ingested breastmilk. Other considerations that may affect infant exposure include the drug’s pharmacokinetics, its duration of administration (usually short term in the postpartum period), the changes in breastmilk composition and volume that occur in the first few days of lactation, and the neonatal oral bioavailability. If a drug has no significant toxic effects and the value of the relative infant dose is <10%, the drug is arbitrarily considered unlikely to be harmful to a postterm breastfed infant, despite the possible immaturity of neonatal metabolic pathways.88
There are several theoretical concerns related to the use of NSAIDs when breastfeeding. Some NSAIDs have antiplatelet effects, so there is a potential effect on neonatal platelet function. Umbilical cord blood from women given ketorolac for labor analgesia shows placental passage of the drug89,90 leading to inhibition of the arachidonic acid and collagen responses, but not the primary adenosine triphosphate platelet response.90 This finding suggests that NSAIDs exhibiting both COX-1 and COX-2 inhibition should not be taken by women who are breastfeeding neonates and infants who have thrombocytopenia or platelet dysfunction. The COX-2–specific inhibitors may be suitable because they show no or less platelet inhibition in adults.91 This class of NSAIDs shows similar analgesic effectiveness and opioid dose-sparing to traditional NSAIDs in non-obstetric settings,92 but after cesarean delivery, studies conflict as to the effectiveness of parecoxib and celecoxib.
Aspirin persists in maternal milk for up to 24 hours and neonatal metabolism is slow.93 Even after a single dose, once lactation is fully established, the infant is exposed to 9% to 21% of the maternal dose.94,95 Toxic effects on breastfed infants exposed to larger doses of salicylates (2–4 g/d) have been known since the 19th century, but there is only 1 case report attributing infant toxicity from metabolic acidosis to a high serum salicylate.96 The mother was taking high-dose aspirin (650 mg 4 hourly), but maternal concentrations were not assayed and it is thought to be very unlikely that the measured infant concentration could have resulted from breastfeeding alone. Adverse effects of aspirin on neonatal platelet function are a theoretical risk that has not been studied. The American Academy of Pediatrics classifies aspirin under drugs that “have been associated with significant effects on some nursing infants and should be given to nursing mothers with caution.”5 Because of the theoretical risk of the Reye syndrome, the British National Formulary states that it should be avoided when breastfeeding.7 Expert opinion is that drugs such as ibuprofen are preferable.97
Indomethacin has limited lipid solubility, high plasma protein binding, and is highly ionized at normal plasma pH, resulting in a median milk to plasma ratio of 0.37. Infant plasma concentrations are usually below the level of quantification (20 µg/L), and the relative infant dose is <1%.98 This level of exposure is equivalent to <10% of the therapeutic dose used in infants to manage patent ductus arteriosus. A case report suggesting indomethacin-induced seizures in a 7-day-old infant whose mother was taking 200 mg/d99 has been criticized because objective evidence of exposure was not confirmed. Indomethacin is considered “probably compatible”7 or “usually compatible”5 with short-term use when breastfeeding.
Maternal ingestion of ibuprofen 400 mg 6 hourly is detectable in breastmilk at a lower limit of quantification of 2.5 ng/mL,100 and the maternal weight-adjusted relative infant dose is <1%, even after repeat maternal dosing (400 mg 6 times over the first 2 postoperative days and twice daily for 3 weeks).100–102 Furthermore, ibuprofen is approved as a therapeutic drug for children, so it is classified as compatible or usually compatible with breastfeeding.5,6 A drug of similar class, flurbiprofen, has been evaluated after both single and repeat dose and transfer into milk is very low, with recovery of <0.1% of the maternal dose in breastmilk.103 Exposure to ketoprofen is likewise very low (relative infant dose <0.5%),104 as is that to fenoprofen.105
Diclofenac is of similar class to indomethacin, has a short 1-hour adult half-life, and results in a relative infant dose of 1.2%.106 Naproxen concentrations in breastmilk peak approximately 4 hours after a maternal dose of 250 to 375 mg, but <0.3% of the maternal dose is excreted in the infant’s urine.107 The product information of tenoxicam states that it appears in breastmilk in low concentration. Piroxicam excretion into breastmilk is very low (milk concentration approximately 1% of the maternal plasma concentration),108 but the drug has a long half-life. Tolmetin has low lipid solubility and very high protein binding, so breastmilk transfer is very low and the estimated relative infant dose only 0.4%.109 Flufenamic acid is highly protein bound and shows very low transfer into breastmilk.110 All these NSAIDs are classified as suitable for early postpartum use (Table 6).
Ketorolac tromethamine has a molecular weight of 376 Da, pKa 3.54, and is 99% plasma protein bound. A dose of 10 mg 4 times a day, for 2 to 6 days after delivery, results in milk to plasma ratios of 0.016 to 0.027. Milk concentrations are below the lower limit of quantification in some women, and relative infant dose (0.18%) is very low.111
Despite this reassuring information, and a recommendation to the contrary within the American Academy of Pediatrics Policy Statement on the transfer of drugs and other chemicals into human milk,5 the United States FDA-approved product information has a “black box” warning stating that ketorolac is contraindicated in nursing mothers because of the potential adverse effects of prostaglandin-inhibiting drugs on neonates. Similar statements appear in the United Kingdom regulatory material; in Australia, the drug is not recommended.
Among the COX-2–specific inhibitors, celecoxib is excreted into breastmilk but is largely eliminated from both plasma and milk by 12 hours from last exposure, and plasma concentrations in the infant may decrease below the limit of detection within 4 hours. A maternal dose of 100 mg twice daily has been estimated to produce a maximum infant dose of 40 µg/kg/d; measured median absolute infant doses after a maternal dose of 200 mg were 10 to 13 µg/kg/d.112–114 Thus, the relative infant dose is only 0.2% to 0.3% of the weight-adjusted maternal dose and 0.2% to 0.6% of the off-label dose of celecoxib (typically 2–6 mg/kg/d) used in children to treat pain and inflammation.115
Concentrations of the prodrug parecoxib in early human milk lie below the limit of quantification in most women,116 and the transfer of its active metabolite valdecoxib is consistent with its molecular weight of 314 Da, lipid solubility, and 8-hour elimination half-life. However, the combined relative infant dose of parecoxib and valdecoxib is very low (0.63%), and in the apparent absence of any detrimental infant effect after exposure to a single 40-mg dose of parecoxib on the third or fourth day after cesarean delivery, it is unlikely the exposed infant will be harmed.116 There is no information about repeat dosing or use later in the puerperium, when breastmilk is mature and production maximal.
In summary, short-term maternal administration of most NSAIDs, apart from aspirin in doses above 150 mg/d, is considered to be of low risk to the breastfed infant (Table 6).
Many NSAIDs have proven effective against postpartum pain caused by episiotomy or other perineal trauma,117–119 uterine involution,120,121 cesarean delivery, or incidental causes (e.g., migraine or rheumatoid arthritis). After rectal NSAID suppositories, perineal pain is reduced for 48 hours, and less additional analgesia is required.122 Ibuprofen 400 mg 6 hourly appears as effective as acetaminophen and codeine, but shows a better side effect profile, for pain from perineal injury.123 Oral celecoxib 200 mg 12 hourly may be a better choice than oral diclofenac 100 mg 12 hourly in the first 24 hours after perineal repair, based on a randomized trial that found less initial rest pain and fewer upper gastrointestinal symptoms.124 Ketorolac is more effective than aspirin 650 mg for postpartum uterine pain.125 A meta-analysis of 9 trials investigating postlaparotomy pain in non-obstetric patients indicated that analgesia was better and side effects reduced with NSAIDs compared with acetaminophen (paracetamol) and codeine.126
As a primary analgesic method after cesarean delivery, an NSAID-based regimen has the benefit of low cost and a superior side effect profile to some systemic opioid methods (e.g., IM meperidine or oral codeine)127–129 or oral tramadol regimens,130 but the analgesia is frequently inadequate.131,132 In contrast, as adjuncts within a multimodal analgesic regimen, NSAIDs are frequently of benefit. The addition of an NSAID improves IV tramadol or opioid analgesia and/or reduces opioid dose requirements after epidural,133 general,134–136 or spinal anesthesia.137–142 There may be a benefit from combining an NSAID with acetaminophen,143,144 although this appears to depend on what concurrent analgesic method is used. As adjuncts to a primary method of systemic opioid, such as IV morphine patient-controlled analgesia, ketorolac, parecoxib, celecoxib, or ibuprofen show similar analgesic effectiveness or opioid dose-sparing effects.145–147 IV diclofenac can augment analgesia achieved with continuous bupivacaine wound infusion.148
When neuraxial opioid techniques are the primary method of postoperative analgesia, the benefits of NSAIDs are much less consistent among both non-obstetric and obstetric surgical populations. Three studies have reported improved analgesia from low-dose epidural morphine with the addition of either diclofenac or ketorolac.131,149,150 Rectal NSAIDs prolonged the time until request for additional analgesia after spinal morphine.151,152 In contrast, after spinal morphine 100 µg, neither IV ketorolac153 nor oral valdecoxib154 had beneficial effects, and celecoxib 300 mg did not improve analgesia.155 Although some studies have found a small dose-sparing effect, pain relief is not improved by combining diclofenac with patient-controlled epidural local anesthetic and opioid.156 Neither IV ketorolac, nor parecoxib followed by oral celecoxib, improved meperidine patient-controlled epidural analgesia or reduced opioid consumption (M. Paech, unpublished data).157
Failure to demonstrate improved analgesia when an NSAID is used with a neuraxial opioid technique likely reflects the high quality of analgesia achieved with the primary method. Subsequently however, as postoperative pain wanes, there may be a role for NSAIDs. Twenty-four hours after spinal morphine, regular oral naproxen reduced incisional pain, cramping pain, and worst pain compared with placebo and modestly reduced rescue opioid requirements, although the incidence of inadequate pain control was not reduced.158
An opioid dose-sparing effect is of no clinical benefit unless the lower opioid dose translates to a better patient outcome because of fewer opioid-induced side effects. One small single-blinded randomized trial found that the intraoperative, postdelivery administration of NSAID (flurbiprofen) was more effective in producing transient improvement in emetic symptoms compared with metoclopramide or droperidol,159 but the finding has not been replicated, and an etiology for this effect is unclear.
There is no information about the incidence of adverse effects in women after short-term postpartum administration of NSAIDs; in particular, safety data with respect to events such as acute gastric ulceration, acute renal impairment, or exacerbation of hypertension are lacking. A 1991 case series160 describes 3 women with the rare complication of necrotizing fasciitis of their abdominal wall after cesarean delivery, all of whom were receiving an NSAID. The authors postulated that there might be a possible causal relationship because NSAIDs impair chemotaxis, phagocytosis, and granulocyte bactericidal activity,161 but there have been no similar reports in the past 20 years.
The inflammatory response in the wound, which includes the release of substance P and various cytokines, is modified by the direct application of local anesthetic.162 A novel approach to peripheral inhibition of inducible COX expression in immune cells and fibroblasts at peripheral sites of injury, to reduce the production of sensitizing prostaglandins, is the wound infusion or infiltration of NSAID.163,164 A 48-hour infusion of diclofenac 300 mg, via a multiholed catheter, superficial to the fascia within a Pfannenstiel incision, resulted in similar analgesia to an infusion of ropivacaine, supplemented by IV diclofenac, and superior pain control and opioid dose-sparing to systemic diclofenac alone.164 Although diclofenac wound infusion did not reduce punctate hyperalgesia around the wound (compared with a ropivacaine infusion or IV diclofenac),164 systemic diclofenac and tramadol combined are more effective than either drug alone in preventing wound sensitization.138 Whether this has benefits in preventing persistent pain has not been investigated.
Experimental work suggests that targeting spinal COX-2, to reduce central prostaglandin production and endogenous cannabinoid breakdown, might be useful in reducing wound hyperalgesia and acute visceral pain from the uterine cervix.165 The potential to treat postoperative pain with intrathecal COX-1 inhibitors has been confirmed in animal models,166 but the first human trial, using spinal ketorolac, produced negative results.167 Nevertheless, this area of investigation is likely to continue.
There is experimental and animal evidence (level 5) that NSAID use during preconception reduces fertility and evidence from case-control studies (level 3b) that consumption of these drugs in early pregnancy is associated with increased rates of spontaneous abortion. The second trimester use of NSAIDs appears relatively safe, although recent level 2b evidence has identified an association with infant cryptorchism. Second and, particularly, third trimester NSAID use may be associated with neonatal renal impairment in premature infants. Use of low-dose aspirin from early pregnancy by women at high risk for preeclampsia appears to reduce the incidence and severity of preeclampsia and growth restriction without causing harm, but because of fetal and neonatal bleeding risks it has been recommended that higher doses of aspirin (>150 mg/d) during pregnancy be avoided (level 4). Considerable caution with regard to third trimester use of NSAIDs is recommended. These drugs should preferably be avoided because of a large and consistent body of level 2b evidence indicating an increased risk of adverse effects, including PPHN and renal injury.
It appears systemic NSAIDs are of no value (level 1b) and potentially harmful if administered during labor analgesia, but level 1a evidence supports their effectiveness for postpartum analgesia after perineal injury. Depending on the primary analgesic method used after cesarean delivery and the timing of administration in the postoperative period, NSAIDs have the potential to reduce pain intensity, opioid requirements (and hence either maternal opioid-related side effects or neonatal exposure through breastmilk), or both (level 1a). However, NSAIDs can worsen hypertension and cause renal dysfunction; so they are best avoided in women with preeclampsia or renal disease (level 4).
Maternal use of NSAIDs during early lactation appears safe for healthy term neonates, given that the relative infant doses of all NSAIDs studied to date have been low and below the limit considered to be acceptable for drugs with a low risk of toxicity. Avoidance of high-dose aspirin when breastfeeding has been recommended (level 4), but low-dose aspirin may be warranted if the individual risk–benefit assessment appears favorable (level 5).
a US Food and Drug Administration. For consumers. Available at: http://www.fda.gov/ForConsumers/ByAudience/ForWomen/ucm118567.htm Accessed January 13, 2013.
b Centre for evidence based medicine. Levels of evidence (March 2009). Available at: http://www.cebm.net/index.aspx?o=1025 Accessed January 13, 2013.
c Royal College of Obstetricians and Gynaecologists. The investigation and treatment of couples with recurrent first-trimester and second-trimester miscarriage. Available at: http://www.rcog.org.uk/files/rcog-corp/GTG17recurrentmiscarriage.pdf Accessed January 13, 2013.
d Royal College of Obstetricians and Gynaecologists. Tocolysis for women in preterm labour. Available at: http://www.rcog.org.uk/files/rcog-corp/GTG1b26072011.pdf. Accessed January 13, 2013.
e US Food and Drug Administration. Drugs. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm125225.htm. Accessed January 13, 2013.
1. Glover DD, Amonkar M, Rybeck BF, Tracy TS. Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J Obstet Gynecol. 2003;188:1039–45
2. Temprano KK, Bandlamudi R, Moore TL. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum. 2005;35:112–21
3. Higby K, Xenakis EM, Pauerstein CJ. Do tocolytic agents stop preterm labor? A critical and comprehensive review of efficacy and safety. Am J Obstet Gynecol. 1993;168:1247–56
4. Østensen ME, Skomsvoll JF. Anti-inflammatory pharmacotherapy during pregnancy. Expert Opin Pharmacother. 2004;5:571–80
5. Committee on Drugs, American Academy of Pediatrics. . The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–89
6. Briggs GG, Freeman RK, Yaffe SJ Drugs in Pregnancy and Lactation. 20119th ed Philadelphia Lippincott Williams and Wilkins
7. British Medical Association and the Royal Pharmaceutical Society of Great Britain. . Prescribing in breast feeding. In: British National Formulary. 201162nd ed UK BMJ Publishing Group
8. Cashman JN. The mechanisms of action of NSAIDs in analgesia. Drugs. 1996;52 Suppl 5:13–23
9. Gan TJ. Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin. 2010;26:1715–31
10. Maves TJ, Pechman PS, Meller ST, Gebhart GF. Ketorolac potentiates morphine antinociception during visceral nociception in the rat. Anesthesiology. 1994;80:1094–101
11. Moren J, Francois T, Blanloeil Y, Pinaud M. The effects of a nonsteroidal antiinflammatory drug (ketoprofen) on morphine respiratory depression: a double-blind, randomized study in volunteers. Anesth Analg. 1997;85:400–5
12. Deussen AR, Ashwood P, Martis R. Analgesia for relief of pain due to uterine cramping/involution after birth. Cochrane Database Syst Rev. 2011:CD004908
13. De Oliveira GS Jr, Agarwal D, Benzon HT. Perioperative single dose ketorolac to prevent postoperative pain: a meta-analysis of randomized trials. Anesth Analg. 2012;114:424–33
14. Elia N, Lysakowski C, Tramèr MR. Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials. Anesthesiology. 2005;103:1296–304
15. Marret E, Kurdi O, Zufferey P, Bonnet F. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: meta-analysis of randomized controlled trials. Anesthesiology. 2005;102:1249–60
16. Maund E, McDaid C, Rice S, Wright K, Jenkins B, Woolacott N. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review. Br J Anaesth. 2011;106:292–7
17. Reese J, Zhao X, Ma WG, Brown N, Maziasz TJ, Dey SK. Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice. Endocrinology. 2001;142:3198–206
18. Gaytán M, Morales C, Bellido C, Sánchez-Criado JE, Gaytán F. Non-steroidal anti-inflammatory drugs (NSAIDs) and ovulation: lessons from morphology. Histol Histopathol. 2006;21:541–56
19. Diao HL, Zhu H, Ma H, Tan HN, Cong J, Su RW, Yang ZM. Rat ovulation, implantation and decidualization are severely compromised by COX-2 inhibitors. Front Biosci. 2007;12:3333–42
20. Martini AC, Vincenti LM, Santillán ME, Stutz G, Kaplan R, Ruiz RD, de Cuneo MF. Chronic administration of nonsteroidal-antiinflammatory drugs (NSAIDS): effects upon mouse reproductive functions. Rev Fac Cien Med Univ Nac Cordoba. 2008;65:47–59
21. Stone S, Khamashta MA, Nelson-Piercy C. Nonsteroidal anti-inflammatory drugs and reversible female infertility: is there a link? Drug Saf. 2002;25:545–51
22. Norman RJ, Wu R. The potential danger of COX-2 inhibitors. Fertil Steril. 2004;81:493–4
23. Schisterman EF, Gaskins AJ, Whitcomb BW. Effects of low-dose aspirin in in-vitro fertilization. Curr Opin Obstet Gynecol. 2009;21:275–8
24. Poustie VJ, Dodd S, Drakeley AJ. Low-dose aspirin for in vitro fertilisation. Cochrane Database Syst Rev. 2007;4:CD004832
25. Akande V, Garas A, Cahill D. The effect of diclofenac and paracetamol on pregnancy and implantation rates in infertile women undergoing IVF treatment. J Obstet Gynaecol. 2006;26:785–7
26. Kailasam C, Hunt LP, Ryder I, Bhakri I, Gordon UD. Safety and effectiveness of diclofenac sodium in assisted reproduction treatment: a randomized prospective double-blind study. Reprod Biomed Online. 2008;16:724–9
27. Dal Prato L, Borini A. Effect of piroxicam administration before embryo transfer on IVF outcome: a randomized controlled trial. Reprod Biomed Online. 2009;19:604–9
28. Vroom F, van den Berg PB, de Jong-van den Berg LT. Prescribing of NSAIDs and ASA during pregnancy; do we need to be more careful? Br J Clin Pharmacol. 2008;65:275–6
29. Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol. 2005;193:771–7
30. Siu SS, Yeung JH, Lau TK. A study on placental transfer of diclofenac in first trimester of human pregnancy. Hum Reprod. 2000;15:2423–5
31. Siu SS, Yeung JH, Lau TK. An in-vivo study on placental transfer of naproxen in early human pregnancy. Hum Reprod. 2002;17:1056–9
32. Nielsen GL, Sørensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ. 2001;322:266–70
33. Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2003;327:368
34. Nakhai-Pour HR, Broy P, Sheehy O, Bérard A. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ. 2011;183:1713–20
35. Ofori B, Oraichi D, Blais L, Rey E, Bérard A. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: A nested case-control study. Birth Defects Res B Dev Reprod Toxicol. 2006;77:268–79
36. Bateman DN, McElhatton PR, Dickinson D, Wren C, Matthews JN, O’Keeffe M, Thomas SH. A case control study to examine the pharmacological factors underlying ventricular septal defects in the North of England. Eur J Clin Pharmacol. 2004;60:635–41
37. Werler MM, Mitchell AA, Moore CA, Honein MANational Birth Defects Prevention Study. . Is there epidemiologic evidence to support vascular disruption as a pathogenesis of gastroschisis? Am J Med Genet A. 2009;149A:1399–406
38. Cleves MA, Savell VH Jr, Raj S, Zhao W, Correa A, Werler MM, Hobbs CANational Birth Defects Prevention Study. . Maternal use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), and muscular ventricular septal defects. Birth Defects Res Part A Clin Mol Teratol. 2004;70:107–13
39. van Gelder MM, Roeleveld N, Nordeng H. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and the risk of selected birth defects: a prospective cohort study. PLoS ONE. 2011;6:e22174
40. Cassina M, De Santis M, Cesari E, van Eijkeren M, Berkovitch M, Eleftheriou G, Raffagnato F, Di Gianantonio E, Clementi M. First trimester diclofenac exposure and pregnancy outcome. Reprod Toxicol. 2010;30:401–4
41. Ericson A, Källén BA. Nonsteroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol. 2001;15:371–5
42. Collins E. Maternal and fetal effects of acetaminophen and salicylates in pregnancy. Obstet Gynecol. 1981;58:57S–62S
43. Richards ID. Congenital malformations and environmental influences in pregnancy. Br J Prev Soc Med. 1969;23:218–25
44. Nelson MM, Forfar JO. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. Br Med J. 1971;1:523–7
45. Saxén I. Associations between oral clefts and drugs taken during pregnancy. Int J Epidemiol. 1975;4:37–44
46. Werler MM, Mitchell AA, Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med. 1989;321:1639–42
47. Kallen BAJ, Olausson PO. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol. 2003;17:255–61
48. Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S. Aspirin and congenital malformations. Lancet. 1976;1:1373–5
49. CLASP collaborative group. . Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. Br J Obstet Gynaecol. 1995;102:861–8
50. Thorp JA, Walsh SW, Brath PC. Low-dose aspirin inhibits thromboxane, but not prostacyclin, production by human placental arteries. Am J Obstet Gynecol. 1988;159:1381–4
51. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguère Y. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116:402–14
52. Trevedi NA. A meta-analysis of low dose aspirin for prevention of preeclampsia. J Postgrad Med. 2011;57:91–5
53. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005:CD002859
54. Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril. 2005;83:684–90
55. Stephenson MD, Ballem PJ, Tsang P, Purkiss S, Ensworth S, Houlihan E, Ensom MH. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can. 2004;26:729–34
56. Zuckerman H, Reiss U, Rubinstein I. Inhibition of human premature labor by indomethacin. Obstet Gynecol. 1974;44:787–92
57. King J, Flenady V, Cole S, Thornton S. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database Syst Rev. 2005:CD001992
58. Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother. 2006;40:824–9
59. Mari G, Moise KJ Jr, Deter RL, Kirshon B, Huhta JC, Carpenter RJ Jr, Cotton DB. Doppler assessment of the pulsatility index of the middle cerebral artery during constriction of the fetal ductus arteriosus after indomethacin therapy. Am J Obstet Gynecol. 1989;161:1528–31
60. Simhan HN, Caritis SN. Prevention of preterm delivery. N Engl J Med. 2007;357:477–87
61. Sawdy RJ, Lye S, Fisk NM, Bennett PR. A double-blind randomized study of fetal side effects during and after the short-term maternal administration of indomethacin, sulindac, and nimesulide for the treatment of preterm labor. Am J Obstet Gynecol. 2003;188:1046–51
62. American College of Obstetricians and Gynecologists. . Practice Bulletin 27: Management of preterm labor. Obstet Gynecol. 2012;119:1308–17
63. Kristensen DM, Hass U, Lesné L, Lottrup G, Jacobsen PR, Desdoits-Lethimonier C, Boberg J, Petersen JH, Toppari J, Jensen TK, Brunak S, Skakkebaek NE, Nellemann C, Main KM, Jégou B, Leffers H. Intrauterine exposure to mild analgesics is a risk factor for development of male reproductive disorders in human and rat. Hum Reprod. 2011;26:235–44
64. Boisen KA, Kaleva M, Main KM, Virtanen HE, Haavisto AM, Schmidt IM, Chellakooty M, Damgaard IN, Mau C, Reunanen M, Skakkebaek NE, Toppari J. Difference in prevalence of congenital cryptorchidism in infants between two Nordic countries. Lancet. 2004;363:1264–9
65. vd Heijden AJ, Provoost AP, Nauta J, Grose W, Oranje WA, Wolff ED, Sauer PJ. Renal functional impairment in preterm neonates related to intrauterine indomethacin exposure. Pediatr Res. 1988;24:644–8
66. Bernstein J, Werner AL, Verani R. Nonsteroidal anti-inflammatory drug fetal nephrotoxicity. Pediatr Dev Pathol. 1998;1:153–6
67. Ali US, Khubchandani S, Andankar P, Parekhji S, Dubhalish V, Padhye B. Renal tubular dysgenesis associated with in utero exposure to Nimuselide. Pediatr Nephrol. 2006;21:274–6
68. Boubred F, Vendemmia M, Garcia-Meric P, Buffat C, Millet V, Simeoni U. Effects of maternally administered drugs on the fetal and neonatal kidney. Drug Saf. 2006;29:397–419
69. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 1995;378:406–9
70. Zhang MZ, Wang JL, Cheng HF, Harris RC, McKanna JA. Cyclooxygenase-2 in rat nephron development. Am J Physiol. 1997;273:F994–1002
71. Cuzzolin L, Dal Cerè M, Fanos V. NSAID-induced nephrotoxicity from the fetus to the child. Drug Saf. 2001;24:9–18
72. Peruzzi L, Gianoglio B, Porcellini MG, Coppo R. Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-1 selective inhibitor nimesulide as tocolytic. Lancet. 1999;354:1615
73. Holmes RP, Stone PR. Severe oligohydramnios induced by cyclooxygenase-2 inhibitor nimesulide. Obstet Gynecol. 2000;96:810–1
74. Jacqz-Aigrain E, Guillonneau M, Boissinot C, Bavoux F, Hartmann JF, Blot P. Maternal and neonatal effects of indomethacin administrated during pregnancy. Apropos of 18 cases. Arch Fr Pediatr. 1993;50:307–12
75. Marpeau L, Bouillie J, Barrat J, Milliez J. Obstetrical advantages and perinatal risks of indomethacin: a report of 818 cases. Fetal Diagn Ther. 1994;9:110–5
76. Cuzzolin L, Fanos V, Pinna B, di Marzio M, Perin M, Tramontozzi P, Tonetto P, Cataldi L. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatr Nephrol. 2006;21:931–8
77. Norton ME, Merrill J, Cooper BA, Kuller JA, Clyman RI. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med. 1993;329:1602–7
78. Souter D, Harding J, McCowan L, O’Donnell C, McLeay E, Baxendale H. Antenatal indomethacin–adverse fetal effects confirmed. Aust N Z J Obstet Gynaecol. 1998;38:11–6
79. Van Marter LJ, Leviton A, Allred EN, Pagano M, Sullivan KF, Cohen A, Epstein MF. Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. Pediatrics. 1996;97:658–63
80. Macintyre PE, Schug SA, Scott DA, Visser EJ, Walker SMAPM:SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. Acute Pain Management: Scientific Evidence. 20103rd ed Melbourne Australian and New Zealand College of Anaesthestists and Faculty of Pain Medicine,
81. Rumack CM, Guggenheim MA, Rumack BH, Peterson RG, Johnson ML, Braithwaite WR. Neonatal intracranial hemorrhage and maternal use of aspirin. Obstet Gynecol. 1981;58:52S–6S
82. Sibai BM, Mirro R, Chesney CM, Leffler C. Low-dose aspirin in pregnancy. Obstet Gynecol. 1989;74:551–7
83. Mousavy SM. Indomethacin induces hypertensive crisis in preeclampsia irrespective of prior antihypertensive drug therapy. Am J Obstet Gynecol. 1991;165:1577
84. Schoenfeld A, Freedman S, Hod M, Ovadia Y. Antagonism of antihypertensive drug therapy in pregnancy by indomethacin? Am J Obstet Gynecol. 1989;161:1204–5
85. Ruoff GE. The impact of nonsteroidal anti-inflammatory drugs on hypertension: alternative analgesics for patients at risk. Clin Ther. 1998;20:376–87
86. Walker JJ, Johnston J, Fairlie FM, Lloyd J, Bullingham R. A comparative study of intramuscular ketorolac and pethidine in labour pain. Eur J Obstet Gynecol Reprod Biol. 1992;46:87–94
87. Slattery MM, Friel AM, Healy DG, Morrison JJ. Uterine relaxant effects of cyclooxygenase-2 inhibitors in vitro
. Obstet Gynecol. 2001;98:563–9
88. Bennett PNBennett PN. Use of the monographs on drugs. In: Drugs and Human Lactation. 19962nd ed Amsterdam Elsevier:67–74
89. Walker JJ, Johnstone J, Lloyd J, Rocha CL. The transfer of ketorolac tromethamine from maternal to foetal blood. Eur J Clin Pharmacol. 1988;34:509–11
90. Greer IA, Johnston J, Tulloch I, Walker JJ. Effect of maternal ketorolac administration of platelet function in the newborn. Eur J Obstet Gynecol Reprod Biol. 1988;29:257–60
91. Fenton C, Keating GM, Wagstaff AJ. Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain. Drugs. 2004;64:1231–61
92. Rømsing J, Møiniche S. A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain. Acta Anaesthesiol Scand. 2004;48:525–46
93. Levy G, Garrettson LK. Kinetics of salicylate elimination by newborn infants of mothers who ingested aspirin before delivery. Pediatrics. 1974;53:201–10
94. Berlin CM Jr, Pascuzzi MJ, Yaffe SJ, Excretion of salicylate in human milk. Clin Pharm Ther. 1980;27:245–6
95. Bailey DN, Weibert RT, Naylor AJ, Shaw RF. A study of salicylate and caffeine excretion in the breast milk of two nursing mothers. J Anal Toxicol. 1982;6:64–8
96. Clark JH, Wilson WG. A 16-day-old breast-fed infant with metabolic acidosis caused by salicylate. Clin Pediatr (Phila). 1981;20:53–4
97. Berlin CM, Briggs GG. Drugs and chemicals in human milk. Semin Fetal Neonatal Med. 2005;10:149–59
98. Lebedevs TH, Wojnar-Horton RE, Yapp P, Roberts MJ, Dusci LJ, Hackett LP, Ilett KF. Excretion of indomethacin in breast milk. Br J Clin Pharmacol. 1991;32:751–4
99. Eeg-Olofsson O, Malmros I, Elwin CE, Steen B. Convulsions in a breast-fed infant after maternal indomethacin. Lancet. 1978;2:215
100. Walter K, Dilger C. Ibuprofen in human milk. Br J Clin Pharmacol. 1997;44:211–2
101. Townsend RJ, Benedetti TJ, Erickson SH, Cengiz C, Gillespie WR, Gschwend J, Albert KS. Excretion of ibuprofen into breast milk. Am J Obstet Gynecol. 1984;149:184–6
102. Weibert RT, Townsend RJ, Kaiser DG, Naylor AJ. Lack of ibuprofen secretion into human milk. Clin Pharm. 1982;1:457–8
103. Cox SR, Forbes KK. Excretion of flurbiprofen into breast milk. Pharmacotherapy. 1987;7:211–5
104. Jacqz-Aigrain E, Serreau R, Boissinot C, Popon M, Sobel A, Michel J, Sibony O. Excretion of ketoprofen and nalbuphine in human milk during treatment of maternal pain after delivery. Ther Drug Monit. 2007;29:815–8
105. Rubin A, Chernish SM, Crabtree R, Gruber CM, Helleberg L, Rodda BE, Warrick P, Wolen RL, Ridolfo AS. A profile of the physiological disposition and gastro-intestinal effects of fenoprofen in man. Curr Med Res Opin. 1974;2:529–44
106. Todd PA, Sorkin EM. Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1988;35:244–85
107. Jamali F, Stevens DR. Naproxen excretion in milk and its uptake by the infant. Drug Intell Clin Pharm. 1983;17:910–1
108. Ostensen M. Piroxicam in human breast milk. Eur J Clin Pharmacol. 1983;25:829–30
109. Sagraves R, Waller ES, Goehrs HR. Tolmetin in breast milk. Drug Intell Clin Pharm. 1985;19:55–6
110. Buchanan RA, Eaton CJ, Koeff ST, Kinkel AW. The breast milk excretion on flufenamic acid. Curr Ther Res Clin Exp. 1969;11:533–8
111. Wischnik A, Manth SM, Lloyd J, Bullingham R, Thompson JS. The excretion of ketorolac tromethamine into breast milk after multiple oral dosing. Eur J Clin Pharmacol. 1989;36:521–4
112. Hale TW, McDonald R, Boger J. Transfer of celecoxib into human milk. J Hum Lact. 2004;20:397–403
113. Gardiner SJ, Doogue MP, Zhang M, Begg EJ. Quantification of infant exposure to celecoxib through breast milk. Br J Clin Pharmacol. 2006;61:101–4
114. Knoppert DC, Stempak D, Baruchel S, Koren G. Celecoxib in human milk: a case report. Pharmacotherapy. 2003;23:97–100
115. Lie HKH, Turner SC. Early experience with the use of celecoxib in child and adolescent population. J Pharmacy Prac Res. 2002;32:27–31
116. Paech MJ, Salman S, Ilett KF, O’Halloran SJ, Muchatuta NA. Transfer of parecoxib and its primary active metabolite valdecoxib via transitional breastmilk following intravenous parecoxib use after cesarean delivery: a comparison of naive pooled data analysis and nonlinear mixed-effects modeling. Anesth Analg. 2012;114:837–44
117. Dodd JM, Hedayati H, Pearce E, Hotham N, Crowther CA. Rectal analgesia for the relief of perineal pain after childbirth: a randomised controlled trial of diclofenac suppositories. BJOG. 2004;111:1059–64
118. Searles JA, Pring DW. Effective analgesia following perineal injury during childbirth: a placebo controlled trial of prophylactic rectal diclofenac. Br J Obstet Gynaecol. 1998;105:627–31
119. Harrison RF, Brennan M. Comparison of two formulations of lignocaine spray with mefenamic acid in the relief of post-episiotomy pain: a placebo-controlled study. Curr Med Res Opin. 1987;10:375–9
120. Yeh YC, Chen SY, Lin CJ, Yeh HM, Sun WZ. Differential analgesic effect of tenoxicam on post-cesarean uterine cramping pain between primiparous and multiparous women. J Formos Med Assoc. 2005;104:647–51
121. Huang YC, Tsai SK, Huang CH, Wang MH, Lin PL, Chen LK, Lin CJ, Sun WZ. Intravenous tenoxicam reduces uterine cramps after Cesarean delivery. Can J Anaesth. 2002;49:384–7
122. Heydayati H, Parsons J, Crowther CA. Rectal analgesia for pain from perineal trauma following childbirth. Cochrane Database Syst Rev. 2003:CD003931
123. Peter EA, Janssen PA, Grange CS, Douglas MJ. Ibuprofen versus acetaminophen with codeine for the relief of perineal pain after childbirth: a randomized controlled trial. CMAJ. 2001;165:1203–9
124. Lim SS, Tan PC, Sockalingam JK, Omar SZ. Oral celecoxib versus oral diclofenac for post-perineal repair analgesia after spontaneous vaginal birth: a randomised trial. Aust N Z J Obstet Gynaecol. 2008;48:71–7
125. Bloomfield SS, Mitchell J, Cissell GB, Barden TP, Yee JP. Ketorolac versus aspirin for postpartum uterine pain. Pharmacotherapy. 1986;6:247–52
126. Nauta M, Landsmeer ML, Koren G. Codeine-acetaminophen versus nonsteroidal anti-inflammatory drugs in the treatment of post-abdominal surgery pain: a systematic review of randomized trials. Am J Surg. 2009;198:256–61
127. Gin T, Kan AF, Lam KK, O’Meara ME. Analgesia after caesarean section with intramuscular ketorolac or pethidine. Anaesth Intensive Care. 1993;21:420–3
128. Kantor T, Cavaliere MB, Hopper M, Roepke S. A double-blind parallel comparison of ketoprofen, codeine, and placebo in patients with moderate to severe postpartum pain. J Clin Pharmacol. 1984;24:228–34
129. Rorarius MG, Suominen P, Baer GA, Romppanen O, Tuimala R. Diclofenac and ketoprofen for pain treatment after elective caesarean section. Br J Anaesth. 1993;70:293–7
130. Sammour RN, Ohel G, Cohen M, Gonen R. Oral naproxen versus oral tramadol for analgesia after cesarean delivery. Int J Gynaecol Obstet. 2011;113:144–7
131. Sun HL, Wu CC, Lin MS, Chang CF, Mok MS. Combination of low-dose epidural morphine and intramuscular diclofenac sodium in postcesarean analgesia. Anesth Analg. 1992;75:64–8
132. Bozkurt N, Kurdoglu M, Kurdoglu Z, Kutlusoy F, Biberoglu K. Postoperative pain control after cesarean section: can diclofenac sodium be used instead of meperidine? J Matern Fetal Neonatal Med. 2009;22:1144–50
133. Lowder JL, Shackelford DP, Holbert D, Beste TM. A randomized, controlled trial to compare ketorolac tromethamine versus placebo after cesarean section to reduce pain and narcotic usage. Am J Obstet Gynecol. 2003;189:1559–62
134. Elhakim M, Nafie M. I.v. tenoxicam for analgesia during caesarean section. Br J Anaesth. 1995;74:643–6
135. Sia AT, Thomas E, Chong JL, Loo CC. Combination of suppository diclofenac and intravenous morphine infusion in post-caesarean section pain relief–a step towards balanced analgesia? Singapore Med J. 1997;38:68–70
136. El-Tahan MR, Warda OM, Yasseen AM, Attallah MM, Matter MK. A randomized study of the effects of preoperative ketorolac on general anaesthesia for caesarean section. Int J Obstet Anesth. 2007;16:214–20
137. Luthman J, Kay NH, White JB. The morphine sparing effect of diclofenac sodium following caesarean section under spinal anaesthesia. Int J Obstet Anesth. 1994;3:82–6
138. Wilder-Smith CH, Hill L, Dyer RA, Torr G, Coetzee E. Postoperative sensitization and pain after cesarean delivery and the effects of single im doses of tramadol and diclofenac alone and in combination. Anesth Analg. 2003;97:526–33
139. Belzarena SD. Evaluation of intravenous tenoxicam for postoperative cesarean delivery pain relief. Preliminary report. Reg Anesth. 1994;19:408–11
140. Surakarn J, Tannirandorn Y. Intramuscular diclofenac for analgesia after cesarean delivery: a randomized controlled trial. J Med Assoc Thai. 2009;92:733–7
141. Dahl V, Hagen IE, Sveen AM, Norseng H, Koss KS, Steen T. High-dose diclofenac for postoperative analgesia after elective caesarean section in regional anaesthesia. Int J Obstet Anesth. 2002;11:91–4
142. Olofsson CI, Legeby MH, Nygårds EB, Ostman KM. Diclofenac in the treatment of pain after caesarean delivery. An opioid-saving strategy. Eur J Obstet Gynecol Reprod Biol. 2000;88:143–6
143. Munishankar B, Fettes P, Moore C, McLeod GA. A double-blind randomised controlled trial of paracetamol, diclofenac or the combination for pain relief after caesarean section. Int J Obstet Anesth. 2008;17:9–14
144. Siddik SM, Aouad MT, Jalbout MI, Rizk LB, Kamar GH, Baraka AS. Diclofenac and/or propacetamol for postoperative pain management after cesarean delivery in patients receiving patient controlled analgesia morphine. Reg Anesth Pain Med. 2001;26:310–5
145. Wong JO, Tan TD, Cheu NW, Wang YR, Liao CH, Chuang FH, Watts MP. Comparison of the efficacy of parecoxib versus ketorolac combined with morphine on patient-controlled analgesia for post-cesarean delivery pain management. Acta Anaesthesiol Taiwan. 2010;48:174–7
146. Fong WP, Yang LC, Wu JI, Chen HS, Tan PH. Does celecoxib have pre-emptive analgesic effect after Caesarean section surgery? Br J Anaesth. 2008;100:861–2
147. Alhashemi JA, Alotaibi QA, Mashaat MS, Kaid TM, Mujallid RH, Kaki AM. Intravenous acetaminophen vs oral ibuprofen in combination with morphine PCIA after Cesarean delivery. Can J Anaesth. 2006;53:1200–6
148. Zohar E, Shapiro A, Eidinov A, Fishman A, Fredman B. Postcesarean analgesia: the efficacy of bupivacaine wound instillation with and without supplemental diclofenac. J Clin Anesth. 2006;18:415–21
149. Tzeng JI, Mok MS. Combination of intramuscular Ketorolac and low dose epidural morphine for the relief of post-caesarean pain. Ann Acad Med Singap. 1994;23:10–3
150. Sun HL, Wu CC, Lin MS, Chang CF. Effects of epidural morphine and intramuscular diclofenac combination in postcesarean analgesia: a dose-range study. Anesth Analg. 1993;76:284–8
151. Pavy TJ, Gambling DR, Merrick PM, Douglas MJ. Rectal indomethacin potentiates spinal morphine analgesia after caesarean delivery. Anaesth Intensive Care. 1995;23:555–9
152. Dennis AR, Leeson-Payne CG, Hobbs GJ. Analgesia after caesarean section. The use of rectal diclofenac as an adjunct to spinal morphine. Anaesthesia. 1995;50:297–9
153. Cohen SE, Desai JB, Ratner EF, Riley ET, Halpern J. Ketorolac and spinal morphine for postcesarean analgesia. Int J Obstet Anesth. 1996;5:14–8
154. Carvalho B, Chu L, Fuller A, Cohen SE, Riley ET. Valdecoxib for postoperative pain management after cesarean delivery: a randomized, double-blind, placebo-controlled study. Anesth Analg. 2006;103:664–70
155. Lee LH, Irwin MG, Lim J, Wong CK. The effect of celecoxib on intrathecal morphine-induced pruritus in patients undergoing Caesarean section. Anaesthesia. 2004;59:876–80
156. Lim NL, Lo WK, Chong JL, Pan AX. Single dose diclofenac suppository reduces post-Cesarean PCEA requirements. Can J Anaesth. 2001;48:383–6
157. Pavy TJ, Paech MJ, Evans SF. The effect of intravenous ketorolac on opioid requirement and pain after cesarean delivery. Anesth Analg. 2001;92:1010–4
158. Angle PJ, Halpern SH, Leighton BL, Szalai JP, Gnanendran K, Kronberg JE. A randomized controlled trial examining the effect of naproxen on analgesia during the second day after cesarean delivery. Anesth Analg. 2002;95:741–5
159. Kimura M, Okamoto T, Tsukagoshi H, Sato J, Saito S. Effect of flurbiprofen, metoclopramide and droperidol for nausea and emesis during cesarean section under spinal anesthesia. J Anesth. 2011;25:692–7
160. van Ammers PM, Moore PJ, Sacho H. Necrotising fasciitis after caesarean section–association with non-steroidal anti-inflammatory drugs. A report of 3 cases. S Afr Med J. 1991;80:203–4
161. Solberg CO. Influence of phenylbutazone on the phagocytic and bactericidal activities of neutrophil granulocytes. Acta Pathol Microbiol Scand B Microbiol Immunol. 1974;82:258–62
162. Carvalho B, Clark DJ, Yeomans DC, Angst MS. Continuous subcutaneous instillation of bupivacaine compared to saline reduces interleukin 10 and increases substance P in surgical wounds after cesarean delivery. Anesth Analg. 2010;111:1452–9
163. Rackelboom T, Le Strat S, Silvera S, Schmitz T, Bassot A, Goffinet F, Ozier Y, Beaussier M, Mignon A. Improving continuous wound infusion effectiveness for postoperative analgesia after cesarean delivery: a randomized controlled trial. Obstet Gynecol. 2010;116:893–900
164. Lavand’homme PM, Roelants F, Waterloos H, De Kock MF. Postoperative analgesic effects of continuous wound infiltration with diclofenac after elective cesarean delivery. Anesthesiology. 2007;106:1220–5
165. Du D, Eisenach JC, Ririe DG, Tong C. The antinociceptive effects of spinal cyclooxygenase inhibitors on uterine cervical distension. Brain Res. 2004;1024:130–6
166. Zhu X, Conklin DR, Eisenach JC. Preoperative inhibition of cyclooxygenase-1 in the spinal cord reduces postoperative pain. Anesth Analg. 2005;100:1390–3
167. Eisenach JC, Curry R, Rauck R, Pan P, Yaksh TL. Role of spinal cyclooxygenase in human postoperative and chronic pain. Anesthesiology. 2010;112:1225–33